drugset
drugset / Trial / NCT06337630

A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors

NCT06337630 ↗

Phase 1 Terminated 10 enrolled Institut Curie Merck Sharp & Dohme LLC · collabProLynx LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

Phase I with a dose finding cohort, followed by expansion cohorts in pre-specified tumor types.

Timeline

Start
2025-01-20
Primary completion
2025-11-24
Completion
2025-11-24

Drugs

EvaluationDrugModalityDoseRoute
Subject DFP-13318 Other / unclassified 800 mg/m2 Intravenous
Subject DFP-13318 Other / unclassified 1000 mg/m2 Intravenous
Subject DFP-13318 Other / unclassified 1300 mg/m2 Intravenous
Subject DFP-13318 Other / unclassified 1700 mg/m2 Intravenous
Subject Tuvusertib Small molecule 90 mg Oral
Subject Tuvusertib Small molecule 130 mg Oral
Subject Tuvusertib Small molecule 180 mg Oral

Indications

cancer